General
Preferred name
VERAPAMIL
Synonyms
VERAPAMIL HYDROCHLORIDE ()
(±)-Verapamil hydrochloride ()
Dexverapamil ()
(¡À)-Verapamil hydrochlorid ()
NSC 135784 ()
NSC-135784 ()
CP-16533-1 ()
(±)-Verapamil ()
Manidon ()
(±)-Verapamil hydrochlorid ()
Verapamil HCl ()
Calcan hydrochloride ()
Verapamyl hydrochloride ()
(±)-Verapamil hydrochloride ()
Benzeneacetonitrile, Alpha-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-Alpha-(1-methylethyl)-, (R)- ()
Verapamil (hydrochloride) ()
(±)-Verapamil (hydrochloride) ()
CP-16533-1 (hydrochloride) ()
(¡À)-Verapamil hydrochloride ()
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitril ()
Verapamil (CP-16533-1) HCl ()
Verapamil (hydrochloride) ()
(±)-Verapamil-d3 (hydrochloride) ()
Cordilox ()
Zolvera ()
Geangin ()
Vertab SR 240 ()
Isoptin ()
Calan ()
Verapamili hydrochloridum ()
Securon ()
Verelan ()
Covera ()
Securon SR ()
Isoptin Sr ()
NSC-657799 ()
Univer ()
Cordilox MR 240 ()
Verapamil hydrochloride component of tarka ()
Securon IV ()
Verapress MR 240 ()
LU-20175 ()
Manidon SR ()
Covera-HS ()
Ethimil MR 240 ()
Calan Sr ()
NSC-272366 ()
Verelan pm ()
Vera-Til SR ()
Berkatens ()
Securon Mid ()
Cordilox I.V. ()
Ranvera MR ()
Half Securon SR ()
(¡À)-Verapamil ()
(¡À)-Verapamil (hydrochloride) ()
D-365 ()
Verapamil slow release ()
Verapamilo ()
NSC-272306NA ()
CP-16,533-1 ()
Iproveratril ()
CP-165331 ()
P&D ID
PD009864
CAS
152-11-4
52-53-9
56949-77-0
38176-10-2
2714485-49-9
Tags
available
drug
Approved by
FDA
First approval
1981
Drug indication
Atrial fibrillation
Hypertension
Coronavirus Disease 2019 (COVID-19)
Cardiovascular disease
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Verapamil hydrochloride ((¡À)-Verapamil hydrochloride) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil hydrochloride also inhibits CYP3A4. Verapamil hydrochloride has the potential for high blood pressure, heart arrhythmias and angina research[1][2][3].
PRICE 29
DESCRIPTION The approved drug verapamil is a racemic mixture of two enantiomers (PubChem CID 92305 and PubChem CID 65808). The structure shown here does not specify stereochemistry and represents the mixture. Marketed formulations may contain verapamil hydrochloride (PubChem CID 62969). (GtoPdb)
PRICE 29
DESCRIPTION Verapamil ((¡À)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research[1][2][3].
DESCRIPTION L-type Ca2+ channel modulator; adrenoceptor antagonist; antiarryhthmic; cardiac depressant; coronary vasodilator (LOPAC library)
DESCRIPTION P2X antagonist (Tocris Bioactive Compound Library)
DESCRIPTION Verapamil is a non-dihydropyridine calcium channel blocker used in the treatment of angina, arrhythmia, and hypertension. (Enamine Bioactive Compounds)
DESCRIPTION Verapamil hydrochloride (Verapamil HCl) is a calcium channel blocker that is a class IV anti-arrhythmia agent. (TargetMol Bioactive Compound Library)
DESCRIPTION Verapamil (CP-16533-1) is a calcium channel blocker and an orally active and effective inhibitor of P-gp. Verapamil inhibits CYP3A4 and can be used in studies about the treatment of high blood pressure, heart arrhythmias, and angina research. (TargetMol Bioactive Compound Library)
Cell lines
34
Organisms
9
Compound Sets
36
Axon Medchem Screening Library
3452
Cayman Chemical Bioactives
14288
18452
ChEMBL Approved Drugs
CHEMBL1280
CHEMBL6966
ChEMBL Drugs
CHEMBL1280
CHEMBL6966
Concise Guide to Pharmacology 2017/18
2406
Concise Guide to Pharmacology 2019/20
2406
Concise Guide to Pharmacology 2021/22
2406
Concise Guide to Pharmacology 2023/24
2406
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB00661
DrugBank Approved Drugs
DB00661
DrugCentral
2815
DrugCentral Approved Drugs
2815
DrugMAP
DM0ASTP
DMA7PEW
DrugMAP Approved Drugs
DMA7PEW
DrugMatrix
Enamine Bioactive Compounds
EBC-12798
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101717
Guide to Pharmacology
2406
Ki Database
VERAPAMIL
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL6966
MedChem Express Bioactive Compound Library
HY-A0064
HY-14275
NCATS Inxight Approved Drugs
CJ0O37KU29
NIH Clinical Collections (NCC)
NIH Mechanistic Set
Novartis Chemogenetic Library (NIBR MoA Box)
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
verapami-hcl
TargetMol Bioactive Compound Library
T1010
T20656
The Spectrum Collection
Tocris Bioactive Compound Library
0654
VGSC-DB
NA0014
External IDs
83
Properties
(calculated by RDKit )
Molecular Weight
454.28
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
0
Rotatable Bonds
13
Ring Count
2
Aromatic Ring Count
2
cLogP
5.09
TPSA
63.95
Fraction CSP3
0.52
Chiral centers
1.0
Largest ring
6.0
QED
0.42
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
L-type
Target
CYP3A4
Calcium Channel
P-gp
Cytochrome P450
P-gp (P-glycoprotein)
CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CYP3A4, KCNA10, KCNA7, KCNH2, KCNJ11, NALCN, SCN5A, SLC29A4, SLC6A4
Ca channel antagonist
P-glycoprotein
Calcium Channel,P450 (e.g. CYP17),P-gp
Primary Target
CaV1.x Channels (L-type)
MOA
Blocker
Dopamine D2 Antagonists
L-Type Calcium Channel Blockers
Calcium Channel Blockers
calcium channel blocker
Member status
member
Indication
hypertension
Pathway
Membrane Transporter/Ion Channel
Metabolism
Neuroscience
Metabolic Enzyme/Protease
Neuronal Signaling
Therapeutic Class
Analgesics
Antiviral Agents
VGSC Target
Nav1.5
Source data